Startup
Dx4Life
Rapid analyses of human genetic variants
In Europe, approximately 1 million in vitro fertilization (IVF) treatments are done annually, and the number is increasing every year. Prior to IVF, women are administered high doses of hormones. However, the majority of hormone treatments for IVF fail.
Clinical studies have highlighted the potential value of genotyping patients prior to IVF or other reproductive therapy – but there is currently no clinically useful marker for the choice of hormone. Dx4Life’s diagnostic test devices for genetic analyzes is intended for rapid genotyping of women undergoing assisted reproduction, egg donation or egg freezing for later use. Subsequently, the most beneficial type of hormonal therapy can be advised.
The company’s first product, Dx4IVF, is intended to be used at IVF clinics to determine the most beneficial type of hormone for women undergoing assisted reproduction by analyzing DNA – and by doing so, the chances to deliver a child increases significantly while the need for repeated trials decreases.
Professor Yvonne Lundberg Giwercman has a PhD in Clinical Genetics from Karolinska Institute, Stockholm. She was appointed professor at Lund University, Medical Faculty in 2018 and has been the head of the research group Molecular Genetic Reproductive Medicine at the same university since 2009. Her main research contributions have been on androgen resistance and ambiguous genitalia in boys, and on reproductive issues in both men and women
Did you know?
Most IVF-trials fail and the side-effects can be serious.